Catheter Precision (NYSEAMERICAN:VTAK) Stock Price Down 2.2% – What’s Next?

Catheter Precision, Inc. (NYSEAMERICAN:VTAK)’s share price was down 2.2% during trading on Tuesday . The company traded as low as $0.9496 and last traded at $0.9971. Approximately 79,507 shares changed hands during trading, a decline of 12% from the average daily volume of 90,467 shares. The stock had previously closed at $1.02.

Catheter Precision Stock Performance

The business has a 50 day moving average of $0.94 and a 200 day moving average of $1.52. The company has a market capitalization of $2.88 million, a P/E ratio of -0.08 and a beta of -1.01. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.35.

Catheter Precision (NYSEAMERICAN:VTAK) last released its quarterly earnings data on Monday, May 18th. The company reported ($1.39) EPS for the quarter, beating the consensus estimate of ($20.90) by $19.51. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $1.60 million. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%.

Institutional Investors Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision at the end of the most recent quarter. Institutional investors own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.